Today we presented preclinical data associated with our TLR7 ISACs technology. The poster presentation titled “Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)” shows the potential of using novel purine-based TLR7 agonists as payloads for ISACs.
ISACs consist of antibodies conjugated to immune stimulants and are designed to induce antitumor immune response. Despite promising preclinical results, ISAC clinical development has been hampered by systemic toxicities or lack of efficacy. Substituted purines have previously been identified as a privileged scaffold to elicit TLR7 activation. The preclinical data presented today, demonstrates newly designed purine-based TLR7 agonists conjugated to trastuzumab which show significant tumor volume reduction in a HER2-high gastric cancer xenograft model without associated body weight loss (BWL) in animal models.
Key data highlights:
Additional information on the TLR7 ISACs technology is available in our October 20, 2022 early R&D day presentation (listen to the webcast). For further information, or to learn more about potential partnership opportunities, please reach out to email@example.com.